加载中
Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically those driven by RAS and/or RAF gene mutations. The second is IMM-6-415, which is being developed to treat solid tumors. Beyond these advanced-stage programs, Immuneering's early-stage pipeline includes five oncology initiatives aimed at components of the MAPK or mTOR signaling pathways, along with two neuroscience programs, all currently in the discovery phase. Founded in 2008, Immuneering Corporation is headquartered in Cambridge, Massachusetts. It was formerly a subsidiary of Teva Pharmaceutical Industries Limited.
前收盘价
US$3.86
−US$0.08 · -2.03%
盘后
US$3.8851
+US$0.0251 · +0.65%
10月12日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically those driven by RAS and/or RAF gene mutations. The second is IMM-6-415, which is being developed to treat solid tumors. Beyond these advanced-stage programs, Immuneering's early-stage pipeline includes five oncology initiatives aimed at components of the MAPK or mTOR signaling pathways, along with two neuroscience programs, all currently in the discovery phase. Founded in 2008, Immuneering Corporation is headquartered in Cambridge, Massachusetts. It was formerly a subsidiary of Teva Pharmaceutical Industries Limited.
日内区间
当前US$3.86
52周区间
当前US$3.86
盘中时间采用ET。市场数据可能有所延迟。
Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically those driven by RAS and/or RAF gene mutations. The second is IMM-6-415, which is being developed to treat solid tumors. Beyond these advanced-stage programs, Immuneering's early-stage pipeline includes five oncology initiatives aimed at components of the MAPK or mTOR signaling pathways, along with two neuroscience programs, all currently in the discovery phase. Founded in 2008, Immuneering Corporation is headquartered in Cambridge, Massachusetts. It was formerly a subsidiary of Teva Pharmaceutical Industries Limited.
日内区间
当前US$3.86
52周区间
当前US$3.86
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | — | — | — | 31.7万 USD | 208万 USD |
| 销货成本 | 69.89万 USD | — | — | 15.81万 USD | 115.31万 USD |
| 毛利 | −69.89万 USD | — | — | 15.88万 USD | 92.69万 USD |
| 研究与开发 | 4204.85万 USD | 4796.44万 USD | 4162.4万 USD | 3626.71万 USD | 2654.1万 USD |
| 销售、一般及管理费用 | 1729.82万 USD | 1607.8万 USD | 1676万 USD | 1560.7万 USD | 827.2万 USD |
| 营业费用 | 5867.71万 USD | 6407.14万 USD | 5841.29万 USD | 5190.37万 USD | 3481.3万 USD |
| 利息收入 | 303.94万 USD | 259.33万 USD | 360.7万 USD | 101.45万 USD | 16.99万 USD |
| 折旧和摊销 | 35.38万 USD | 38.51万 USD | 35.21万 USD | 27.73万 USD | 15.91万 USD |
| 营业利润 | −5937.6万 USD | −6407.14万 USD | −5841.29万 USD | −5174.49万 USD | −3388.61万 USD |
| 净利润 | −5602.49万 USD | −6103.66万 USD | −5347.16万 USD | −5051.36万 USD | −3353.57万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI810.16万0.00%2.3万亿 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM565.33万0.01%787.4亿 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF315.23万0.00%954亿 USD0.05%US$233.52-0.63%
iShares Biotechnology ETFIBB176.1万0.02%108.2亿 USD0.44%US$204.26-1.08%
Vanguard Russell 2000 ETFVTWO153.36万0.01%180亿 USD0.06%US$112.27-0.35%
iShares Micro-Cap ETFIWC69.76万0.05%13.17亿 USD0.60%US$181.66-0.73%
ALPS Medical Breakthroughs ETFSBIO32.14万0.17%1.91亿 USD0.50%US$53.85-2.16%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM29万0.25%1.17亿 USD0.73%US$15.8484-0.58%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCALPS Medical Breakthroughs ETFSBIOEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
